|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61K 39/39 | |||
| A61P 35/00 | |||
| A61P 37/02 |
| (11) | Number of the document | 3177321 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15829910.7 |
| Date of filing the European patent application | 2015-08-07 | |
| (97) | Date of publication of the European application | 2017-06-14 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/CA2015/050747 |
| Date | 2015-08-07 |
| (87) | Number | WO 2016/019472 |
| Date | 2016-02-11 |
| (30) | Number | Date | Country code |
| 201462034915 P | 2014-08-08 | US |
| (72) |
MADIYALAKAN, Ragupathy, CA
NICODEMUS, Christopher F., US
|
| (73) |
Oncoquest Pharmaceuticals Inc.,
670-21 Sannae-ro, Sannae-myeon, Miryang-Si,
KR
|
| (54) | TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER |
| TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER |